Page last updated: 2024-11-05

zardaverine and Hypertension, Pulmonary

zardaverine has been researched along with Hypertension, Pulmonary in 1 studies

zardaverine: structure given in first source
zardaverine : A pyridazinone derivative in which pyridazin-3(2H)-one is substituted at C-6 with a 4-(difluoromethoxy)-3-methoxyphenyl group. It is a phosphodiesterase inhibitor, selective for PDE3 and 4.

Hypertension, Pulmonary: Increased VASCULAR RESISTANCE in the PULMONARY CIRCULATION, usually secondary to HEART DISEASES or LUNG DISEASES.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (100.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Schermuly, RT1
Ghofrani, HA1
Enke, B1
Weissmann, N1
Grimminger, F1
Seeger, W1
Schudt, C1
Walmrath, D1

Other Studies

1 other study available for zardaverine and Hypertension, Pulmonary

ArticleYear
Low-dose systemic phosphodiesterase inhibitors amplify the pulmonary vasodilatory response to inhaled prostacyclin in experimental pulmonary hypertension.
    American journal of respiratory and critical care medicine, 1999, Volume: 160, Issue:5 Pt 1

    Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; Administration, Inhalation; Aero

1999